Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Trial Profile

Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Acronyms PRPET
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 21 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 31 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top